SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:lup.lub.lu.se:ca8d080d-3116-434c-907e-f8bb87d62234"
 

Search: onr:"swepub:oai:lup.lub.lu.se:ca8d080d-3116-434c-907e-f8bb87d62234" > Enterostatin decrea...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Enterostatin decreases postprandial pancreatic UCP2 mRNA levels and increases plasma insulin and amylin

Arsenijevic, D (author)
Gallmann, E (author)
Moses, W (author)
show more...
Lutz, T (author)
Erlanson-Albertsson, Charlotte (author)
Lund University,Lunds universitet,Aptitkontroll,Forskargrupper vid Lunds universitet,Appetite Regulation,Lund University Research Groups
Langhans, W (author)
show less...
 (creator_code:org_t)
American Physiological Society, 2005
2005
English.
In: American Journal of Physiology: Endocrinology and Metabolism. - : American Physiological Society. - 1522-1555 .- 0193-1849. ; 289:1, s. 40-45
  • Journal article (peer-reviewed)
Abstract Subject headings
Close  
  • This study investigated the chronic effect of enterostatin on body weight and some of the associated changes in postprandial metabolism. Rats were adapted to 6 h of food access/day and a choice of low-fat and high-fat (HF) food and then given enterostatin or vehicle by an intraperitoneally implanted minipump delivering 160 nmol enterostatin/h continuously over a 5-day infusion period. Enterostatin resulted in a slight but significant reduction of HF intake and body weight. After the last 6-h food access period, enterostatin-treated animals had lower plasma triglyceride and free fatty acid but higher plasma glucose and lactate levels than control animals. Enterostatin infusion resulted in increased uncoupling protein-2 (UCP2) expression in various tissues, including epididymal fat and liver. UCP2 was reduced in the pancreas of enterostatin-treated animals, and this was associated with increased plasma levels of insulin and amylin. Whether these two hormones are involved in the observed decreased food intake due to enterostatin remains to be determined. As lipid metabolism appeared to be altered by enterostatin, we measured peroxisome proliferator-activated receptor (PPAR) expression in tissues and observed that PPAR alpha, -beta, -gamma 1, and -gamma 2 expression were modified by enterostatin in epididymal fat, pancreas, and liver. This further links altered lipid metabolism with body weight loss. Our data suggest that alterations in UCP2 and PPAR gamma 2 play a role in the control of insulin and amylin release from the pancreas. This implies that enterostatin changes lipid and carbohydrate metabolic pathways in addition to its effects on food intake and energy expenditure.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Medicinska och farmaceutiska grundvetenskaper -- Fysiologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Basic Medicine -- Physiology (hsv//eng)

Keyword

peroxisome proliferator-activated
glutathione
body weight
appetite
receptors
uncoupling protein-2

Publication and Content Type

art (subject category)
ref (subject category)

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Find more in SwePub

By the author/editor
Arsenijevic, D
Gallmann, E
Moses, W
Lutz, T
Erlanson-Alberts ...
Langhans, W
About the subject
MEDICAL AND HEALTH SCIENCES
MEDICAL AND HEAL ...
and Basic Medicine
and Physiology
Articles in the publication
American Journal ...
By the university
Lund University

Search outside SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view